Results 11 to 20 of about 1,666,095 (344)

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma

Cancer Cell International, 2022
Background While the correlation between PD-L1 expression and KRAS mutation has been previously reported in other solid tumors such as non-small cell lung cancer (NSCLC), whether PD-L1 can be modulated by ERK signaling downstream of KRAS in intrahepatic ...
Zheng Gao, Jia-Feng Chen, Xiao-Gang Li, Ying-Hong Shi, Zheng Tang, Wei-Ren Liu, Xin Zhang, Ao Huang, Xuan-Ming Luo, Qiang Gao, Guo-Ming Shi, Ai-Wu Ke, Jian Zhou, Jia Fan, Xiu-Tao Fu, Zhen-Bin Ding   +15 more
doaj   +1 more source

LIVER CANCER

Clinics in Liver Disease, 2001
The prognosis of patients with HCC remains dismal. Even in the subgroups of patients who have the most favorable characteristics and are eligible for surgical resection, the 5-year survival rate is less than 25%. For patients with more advanced disease, the median survival time is less than 1 year.
A, Aguayo, Y Z, Patt
openaire   +4 more sources

Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea [PDF]

Journal of Liver Cancer
In 2024, a nationwide conflict between the South Korean government and the medical community, the medical-policy conflict, profoundly impacted healthcare delivery.
Soon Sun Kim, Hyun Yang, Jieun Kwon, Eunju Kim, Jeong Il Yu, Janghan Jung, Woosun Choi, Ji Eun Han, Moon Haeng Hur, Bo Hyun Kim, Sung Hyun Kim, Jeong Han Kim, Haeryoung Kim, Pyoung-Jae Park, Hyun Phil Shin, Su Jong Yu, Ki Tae Yoon, Sang Min Yoon, Minjong Lee, Jai Young Cho, Jin-Young Choi, Do Young Kim, June Sung Lee, Mi-Sook Kim, Kyung Sik Kim   +24 more
doaj   +1 more source

Small Molecule‐Induced Differentiation As a Potential Therapy for Liver Cancer

Advanced Science, 2022
Despite the efficacy demonstrated by immunotherapy recently, liver cancer still remains one of the deadliest cancers, mainly due to heterogeneity of this disease. Continuous exploration of new therapeutics is therefore necessary.
Xu Zhang, Xiang‐Jie Zhu, Zhi Zhong, Jiang‐Chuan Du, Guo‐Xu Fang, Xiu‐liang Cui, Ling‐Ting Guan, Yan‐Yu Hu, Hong‐Yang Wang, Pei‐Lin Zhang   +9 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs).
Sathathone Douangprachanh, Hyun Jin Joo, Hyeong Min Park, Nayoung Han, Hye Young Jang, Young Hwan Koh, Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Jung Won Chun   +11 more
doaj   +1 more source

Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria [PDF]

Journal of Liver Cancer
This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications.
Hyun Yang, Soon Sun Kim, Seong Hee Kang, Jieun Kwon, Do Young Kim, Eunju Kim, Hyun Phil Shin, Jeong Il Yu, Jeong-Ju Yoo, Eileen L. Yoon, Sangheun Lee, Young Eun Chon, Janghan Jung, Jaekyung Cheon, Woosun Choi, Seul Ki Han, Ji Eun Han, Moon Haeng Hur, Hyun Woong Lee, Hyung Joon Kim   +19 more
doaj   +1 more source

Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study

Scientific Reports, 2022
Biliary tract cancer (BTC) has been inconsistently identified according to its location in epidemiological and clinical studies. This study retrospectively reviewed the treatment pattern and prognosis of BTC according to tumor location using the Korea ...
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sun-Whe Kim, Woo Jin Lee, Sang Myung Woo, Tae Hyun Kim, Young-Joo Won, Sang-Jae Park   +9 more
doaj   +1 more source

Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study [PDF]

, 2004
ObjectiveWhile several studies have reported on the relation of diabetes status with pancreatic cancer risk, the predictive value of this disorder for other malignancies is unclear.
A Czyzyk, A Sasaki, AB Lowenfels, AB Lowenfels, Anon, B Armstrong, B Balkau, BA O?Mara, BA O?Mara, C Vecchia LA, DD Reid, DD Reid, DR Cox, E Breeze, E Freund, E Ohmura, E Tabor, F Vegt de, G Davey Smith, G Davey Smith, G Davey Smith, G Davey Smith, G Davey Smith, G Rose, G. David. Batty, GA Rose, GD Batty, GD Batty, GD Batty, GD Batty, GD Batty, George Davey Smith, H Brenner, HO Adami, HO Adami, II Kessler, II Kessler, J Everhart, J Permert, J Permert, J Schafer, JH Fuller, JH Fuller, JH Fuller, K Steenland, L Gullo, L Wideroff, M Mori, M Ragozzino, Martin J. Shipley, MC Yu, MG Marmot, MG Marmot, MG Marmot, Michael Marmot, N Trinkler, NS Weiss, RJ Jarrett, RJ Jarrett, RZ Stolzenber-Solomon, SAS Institute Inc, SH Saydah, SM Gapstur, SS Coughlin, W Fisher, W Levine, WH Chow, Y Lin   +67 more
core   +1 more source

Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

BMC Cancer, 2017
Background Whether perioperative blood transfusions (PBTs) adversely influence oncological outcomes for intrahepatic cholangiocarcinoma (ICC) patients after curative resection remains undetermined. Methods Of the 605 patients who underwent curative liver
Pei-Yun Zhou, Zheng Tang, Wei-Ren Liu, Meng-Xin Tian, Lei Jin, Xi-Fei Jiang, Han Wang, Chen-Yang Tao, Zhen-Bin Ding, Yuan-Fei Peng, Shuang-Jian Qiu, Zhi Dai, Jian Zhou, Jia Fan, Ying-Hong Shi   +14 more
doaj   +1 more source